Swiss National Bank grew its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Get Rating) by 2.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 194,700 shares of the company’s stock after purchasing an additional 4,200 shares during the period. Swiss National Bank’s holdings in Myriad Genetics were worth $2,825,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently made changes to their positions in MYGN. Boston Partners bought a new stake in Myriad Genetics in the 4th quarter valued at $64,000. Arizona State Retirement System boosted its position in shares of Myriad Genetics by 4.2% in the fourth quarter. Arizona State Retirement System now owns 22,753 shares of the company’s stock valued at $330,000 after acquiring an additional 920 shares during the period. Duality Advisers LP acquired a new position in shares of Myriad Genetics in the fourth quarter valued at about $767,000. Fisher Asset Management LLC increased its position in Myriad Genetics by 51.0% during the fourth quarter. Fisher Asset Management LLC now owns 190,383 shares of the company’s stock worth $2,762,000 after acquiring an additional 64,276 shares during the period. Finally, ProShare Advisors LLC raised its stake in Myriad Genetics by 8.8% in the 4th quarter. ProShare Advisors LLC now owns 19,298 shares of the company’s stock worth $280,000 after purchasing an additional 1,554 shares in the last quarter. Institutional investors own 99.08% of the company’s stock.
Myriad Genetics Stock Performance
Shares of MYGN stock opened at $22.68 on Wednesday. Myriad Genetics, Inc. has a fifty-two week low of $13.92 and a fifty-two week high of $28.18. The stock’s fifty day moving average price is $21.67 and its two-hundred day moving average price is $19.88. The company has a market cap of $1.85 billion, a PE ratio of -12.60 and a beta of 1.84.
Insider Activity at Myriad Genetics
In related news, COO Nicole Lambert sold 6,433 shares of the stock in a transaction that occurred on Monday, March 27th. The shares were sold at an average price of $23.48, for a total value of $151,046.84. Following the completion of the transaction, the chief operating officer now owns 240,506 shares of the company’s stock, valued at approximately $5,647,080.88. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.00% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the stock. Stephens increased their target price on shares of Myriad Genetics from $17.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Monday, March 6th. Raymond James increased their price target on Myriad Genetics from $25.00 to $27.00 and gave the stock an “outperform” rating in a research report on Friday, March 3rd. StockNews.com started coverage on Myriad Genetics in a report on Thursday, May 18th. They issued a “hold” rating for the company. Finally, The Goldman Sachs Group raised Myriad Genetics from a “sell” rating to a “buy” rating and increased their target price for the stock from $18.00 to $25.00 in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Myriad Genetics presently has an average rating of “Hold” and an average price target of $26.60.
Myriad Genetics Company Profile
Myriad Genetics, Inc engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk of developing a disease later in life.
- Get a free copy of the StockNews.com research report on Myriad Genetics (MYGN)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN – Get Rating).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.